About this trial
Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery.
Eligibility criteria
Qualifiers
Any adult (18 or older) patients of any gender identity who are undergoing chest masculinizing surgery with double incision and free nipple grafting.
Disqualifiers
Minor patients (younger than 18)
Anyone who's not getting free nipple grafting
Anyone who's not utilizing double incision pattern
Prisoners, anyone who is allergic to nitropaste
Trial design
Treatments tested in this trial
- Nitro-Bid 2 % Topical Ointment